Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage

被引:24
作者
Lewis, Nicole R. [1 ]
Brunker, Patricia [1 ]
Lemire, Susan J. [1 ]
Kaufman, Richard M. [1 ]
机构
[1] Brigham & Womens Hosp, Blood Bank, Dept Pathol, Boston, MA 02115 USA
关键词
ACTIVATED FACTOR-VII; DISSEMINATED INTRAVASCULAR COAGULATION; DOSE FACTOR VIIA; INTERNATIONAL NORMALIZED RATIO; HUMAN FIBRINOGEN CONCENTRATE; CELL-BASED MODEL; FACTOR-X; MANAGEMENT; EFFICACY; TOLERABILITY;
D O I
10.1111/j.1537-2995.2008.02029.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Postpartum hemorrhage (PPH) remains an important cause of maternal morbidity and mortality. Several published reports suggest that recombinant factor VIIa (rFVIIa) is effective in controlling bleeding in PPH. This study reports a case of severe PPH complicated by disseminated intravascular coagulation (DIC), in which early rFVIIa (44 mu g/kg) administration not only failed to control the bleeding in vivo but also, surprisingly, failed to correct the patient's international normalized ratio (INR) in vitro. It was hypothesized that the failure of rFVIIa to correct the INR indicated a deficiency in a downstream coagulation factor(s). To investigate this, coagulation factor levels were measured in blood samples that had been drawn periodically during resuscitation in the operating room. Clinical and laboratory data were extracted from the medical record. Plasma samples that had been obtained during resuscitation were frozen, and activity levels of the following factors were subsequently measured: fibrinogen, FII, FV, FVII, F IX, and FX. After rFVIIa administration, the patient's INR remained elevated at 1.9, and bleeding continued. It was determined that at the time rFVIIa was administered, the patient's fibrinogen level was very low (60 mg/dL). INR normalization and control of bleeding was achieved only after the patient's fibrinogen level was restored to normal. FII, F IX, and FX remained at hemostatic levels throughout resuscitation. In this case of severe PPH complicated by DIC, fibrinogen appears to have been limiting at the time rFVIIa was administered. It is suggested that fibrinogen levels should be corrected during PPH resuscitation before rFVIIa use is considered.
引用
收藏
页码:689 / 695
页数:7
相关论文
共 50 条
[41]   Recombinant Activated Factor VIIa Combined With Tranexamic Acid Control Haemostasis in Patients With Severe Factor XI Deficiency Undergoing Urological Procedures [J].
Sternbach, Neta ;
Ehrlich, Yaron ;
Stenevsky, Anfisa ;
Saidian, Daniel ;
Abd Elhalim, Darawsha ;
Baniel, Jack ;
Raanani, Pia ;
Spectre, Galia .
HAEMOPHILIA, 2025,
[42]   Cost-Effectiveness Analysis of Plasma Versus Recombinant Factor VIIa for Placing Intracranial Pressure Monitors in Pretransplant Patients With Acute Liver Failure [J].
Pham, Huy P. ;
Sireci, Anthony N. ;
Kim, Chong H. ;
Schwartz, Joseph .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2014, 20 (06) :607-614
[43]   Recombinant Factor VIIa Treatment of Severe Bleeding in Cardiac Surgery Patients: A Retrospective Analysis of Dosing, Efficacy, and Safety Outcomes [J].
Masud, Faisal ;
Bostan, Fariedeh ;
Chi, Elisa ;
Pass, Steven E. ;
Samir, Hany ;
Stuebing, Karla ;
Liebl, Michael G. .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2009, 23 (01) :28-33
[44]   Risk Factors for Severe Postpartum Hemorrhage After Cesarean Delivery: Case-Control Studies [J].
Butwick, Alexander J. ;
Ramachandran, Bharathi ;
Hegde, Priya ;
Riley, Edward T. ;
El-Sayed, Yasser Y. ;
Nelson, Lorene M. .
ANESTHESIA AND ANALGESIA, 2017, 125 (02) :523-532
[45]   Rationale for the Potential Use of Recombinant Activated Factor VII in Severe Post-Partum Hemorrhage [J].
Acs, Nandor ;
Korte, Wolfgang C. ;
von Heymann, Christian C. ;
Windyga, Jerzy ;
Blatny, Jan .
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (10)
[46]   Patient with congenital factor VII deficiency undergoing brain tumor neurosurgery successfully treated with recombinant factor VIIa and fresh frozen plasma: A case report and literature review [J].
Huang, Chaoyu ;
Yu, Yongjia ;
Zhai, Ningneng ;
Mo, Wuning ;
Lin, Faquan .
MEDICINE, 2023, 102 (52) :E36694
[47]   Effect of Recombinant Factor VIIa as an Adjunctive Therapy in Damage Control for Wartime Vascular Injuries: A Case Control Study [J].
Fox, Charles J. ;
Mehta, Sumeru G. ;
Cox, E. Darrin ;
Kragh, John F., Jr. ;
Salinas, Jose ;
Holcomb, John B. .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2009, 66 (04) :S112-S119
[48]   Neonatal hemorrhage stroke and severe coagulopathy in a late preterm infant after receiving umbilical cord milking: A case report [J].
Lu, Yan ;
Zhang, Zhi-Qun .
WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (16) :5365-5372
[49]   Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia [J].
Gruppo, R. A. ;
Malan, D. ;
Kapocsi, J. ;
Nemes, L. ;
Hay, C. R. M. ;
Boggio, L. ;
Chowdary, P. ;
Tagariello, G. ;
von Drygalski, A. ;
Hua, F. ;
Scaramozza, M. ;
Arkin, S. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (10) :1984-1993
[50]   Trauma, Transfusions, and Use of Recombinant Factor VIIa: A Multicenter Case Registry Report of 380 Patients from the Western Trauma Association [J].
Knudson, M. Margaret ;
Cohen, Mitchell J. ;
Reidy, Rosemary ;
Jaeger, Sebastian ;
Bacchetti, Peter ;
Jin, Chengshi ;
Wade, Charles E. ;
Holcomb, John B. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2011, 212 (01) :87-95